News
-
-
-
COMMUNIQUÉ DE PRESSE
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
NanoViricides, Inc., a leading global pioneer in broad-spectrum antivirals, achieves significant success in developing a drug against Measles with NV-387. The drug shows strong antiviral effectiveness in recent studies -
-
-
COMMUNIQUÉ DE PRESSE
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
NanoViricides, Inc. comments on WHO's extension of the MPox Public Health Emergency of International Concern and highlights the development of NV-387, a potential broad-spectrum antiviral for MPOX treatment -
-
-
COMMUNIQUÉ DE PRESSE
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
NanoViricides, Inc. announces design completion of adaptive clinical trial protocol for MPox Virus treatment. Trial to evaluate dosing regimen, safety, and effectiveness in 80 patients -
